Background: Cinnamon contact stomatitis (CCS) is a rare reaction to the use of products containing artificial cinnamon flavor ingredients. Such products are gums, toothpastes and mouthwashes. Main observations: A 20-year-old female patient presented with white elevated mucosal patches in the right lateral board of her tongue. Based on anamnesis, the intitial diagnosis of allergy to cinnamon gum was established. Clinical differential diagnosis included hairy leukoplakia, leukoplakia and lichenoid reaction. The patient was advised to completely avoid the use of cinnamon flavoured chewing gums. On re-examination later she had a normal tongue appearance. Conclusion: Clinicians who treat patients with oral conditions should be aware of CCS in order to be able to correctly diagnose and manage this condition. ____________________________________________________ Georgakopoulou EA. Cinnamon contact stomatitis. J Dermatol Case Rep. 2010; 4(2): 28-29.
Head and neck cancer (HNC) represents a challenging oncological entity with significant morbidity and mortality rates. Despite advances in conventional therapies, including surgery, chemotherapy, and radiation therapy, the overall survival rates for advanced HNC remain suboptimal. In recent years, the emerging field of oncolytic virotherapy has gained attention as a promising therapeutic approach for various malignancies, including HNC. This review provides a comprehensive overview of the current understanding of oncolytic viruses (Ovs) in the context of HNC treatment, including their mechanisms of action, preclinical and clinical studies, challenges, and future directions. Future oncolytic virotherapy focuses on improving delivery and specificity through nanoparticle carriers and genetic modifications to enhance tumor targeting and immune response. Combining different OVs and integrating them with immunotherapies, such as checkpoint inhibitors, could overcome tumor resistance and improve outcomes. Personalized approaches and rigorous clinical trials are key to ensuring the safety and effectiveness of virotherapy in treating HNC.
A new human coronavirus, known as severe acute respiratory coronavirus 2 syndrome (SARS‐CoV‐2), emerged at the end of 2019 in Wuhan, China, and we are now facing a pandemic (WHO 2020). The virus has been found in saliva (Meng et al 2020, Sabino et al 2020). In vitro experimental findings suggest that SARS‐CoV‐2 remained viable in aerosols for 3 hours (van Doremalen et al 2020).
22 May 2014 in Journal of Investigative and Clinical Dentistry
Background: Exfoliative and erosive cheilitis, may be a source of speech and chewing discomfort, but may also be an aesthetic issue for the patients affected. Such a clinical presentation may implicate a variety of inflammatory conditions, including atopic (eczematous) cheilitis. Topical and systemic agents, e.g. corticosteroids, have been used to treat inflammatory lip conditions. Topical tacrolimus has also been used in some inflammatory lip conditions. Material and Methods: We performed a retrospective clinical analysis of atopic cheilitis patients. Results: Between 2015 and 2020, we addressed 7 (seven) patients with atopic dermatitis affecting only lips and were diagnosed as atopic-eczematous cheilitis. They were treated with 0.03 per cent topical tacrolimus ointment and responded completely. Conclusions: These cases represent an underreported atopy / eczema event;-few cases of atopic cheilitis without concomitant dermal lesions appear in the literature. We are also showing and discussing yet another application of tacrolimus in a local atopic form of inflammation affecting the lips.